What is the share price of Bal Pharma Ltd (BALPHARMA) today?
The share price of BALPHARMA as on 15th September 2026 is ₹107.44. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bal Pharma Ltd (BALPHARMA) share?
The past returns of Bal Pharma Ltd (BALPHARMA) share are- Past 1 week: 14.57%
- Past 1 month: 23.35%
- Past 3 months: 22.40%
- Past 6 months: 60.45%
- Past 1 year: 22.86%
- Past 3 years: 11.97%
- Past 5 years: 1.17%
What are the peers or stocks similar to Bal Pharma Ltd (BALPHARMA)?
The peers or stocks similar to Bal Pharma Ltd (BALPHARMA) include:What is the dividend yield % of Bal Pharma Ltd (BALPHARMA) share?
The current dividend yield of Bal Pharma Ltd (BALPHARMA) is 1.12.What is the market cap of Bal Pharma Ltd (BALPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bal Pharma Ltd (BALPHARMA) is ₹171.05 Cr as of 15th September 2026.What is the 52 week high and low of Bal Pharma Ltd (BALPHARMA) share?
The 52-week high of Bal Pharma Ltd (BALPHARMA) is ₹124.60 and the 52-week low is ₹60.What is the PE and PB ratio of Bal Pharma Ltd (BALPHARMA) stock?
The P/E (price-to-earnings) ratio of Bal Pharma Ltd (BALPHARMA) is 27.24. The P/B (price-to-book) ratio is 2.21.Which sector does Bal Pharma Ltd (BALPHARMA) belong to?
Bal Pharma Ltd (BALPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bal Pharma Ltd (BALPHARMA) shares?
You can directly buy Bal Pharma Ltd (BALPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bal Pharma Ltd
BALPHARMA Share Price
NSE₹107.440.02% (+0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BALPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
BALPHARMA Performance & Key Metrics
BALPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 23.72 | 2.21 | 1.12% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.37 | 5.81 | 0.49% |
BALPHARMA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BALPHARMA Company Profile
Bal Pharma Limited is engaged in the manufacture and sale of pharmaceutical products. The Company’s business comprises of Active Pharmaceutical Ingredients (API), Finished Formulations, Ayurvedic, Research and Development.
SUNPHARMA
PE Ratio
38.35
38.35
1Y Return
14.54%
14.54%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
85.27
85.27
1Y Return
37.33%
37.33%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
21.75
21.75
1Y Return
5.99%
5.99%
Buy Reco %
57.69
57.69
CIPLA
PE Ratio
28.13
28.13
1Y Return
12.74%
12.74%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
117.14
117.14
1Y Return
115.30%
115.30%
Buy Reco %
58.33
58.33
BALPHARMA Forecast
BALPHARMA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BALPHARMA
BALPHARMA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
BALPHARMA Income Statement
BALPHARMA Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 97.08 | 75.18 | 73.49 | 73.66 | 82.96 | 66.59 | 75.14 | 88.02 | 83.84 | 89.05 | ||||||||||
Operating & Other expenses | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 | 68.29 | 78.14 | 73.51 | 80.67 | ||||||||||
EBITDA | 12.05 | 7.29 | 7.49 | 8.26 | 8.72 | 6.78 | 6.85 | 9.88 | 10.33 | 8.38 | ||||||||||
| Depreciation/Amortization | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 | ||||||||||
| PBIT | 9.89 | 4.86 | 5.01 | 5.57 | 6.54 | 4.26 | 4.58 | 6.65 | 7.27 | 5.60 | ||||||||||
| Interest & Other Items | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 | ||||||||||
| PBT | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.80 | 3.21 | 1.13 | ||||||||||
| Taxes & Other Items | 0.27 | 0.36 | 0.32 | 0.08 | -2.84 | 0.01 | 0.01 | 0.01 | -0.38 | 0.01 | ||||||||||
| Net Income | 5.48 | 0.26 | 1.04 | 0.48 | 5.43 | 0.20 | 0.71 | 1.79 | 3.59 | 1.12 | ||||||||||
| EPS | 3.73 | 0.16 | 0.65 | 0.33 | 3.40 | 0.13 | 0.45 | 1.12 | 2.26 | 0.71 |
BALPHARMA Company Updates
BALPHARMA Stock Peers
BALPHARMA Past Performance & Peer Comparison
BALPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bal Pharma Ltd | 27.24 | 2.21 | 1.12% |
| Sun Pharmaceutical Industries Ltd | 38.35 | 5.25 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.27 | 10.49 | 0.70% |
| Zydus Lifesciences Ltd | 21.75 | 3.71 | 0.09% |
BALPHARMA Stock Price Comparison
Compare BALPHARMA with any stock or ETFCompare BALPHARMA with any stock or ETF
BALPHARMA
BALPHARMA Holdings
BALPHARMA Shareholdings
BALPHARMA Promoter Holdings Trend
BALPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BALPHARMA Institutional Holdings Trend
BALPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BALPHARMA Shareholding Pattern
BALPHARMA Shareholding Pattern
BALPHARMA Shareholding History
BALPHARMA Shareholding History
Foreign Institutions
smallcases containing BALPHARMA stock
smallcases containing BALPHARMA stock
Looks like this stock is not in any smallcase yet.
BALPHARMA Events
BALPHARMA Events
BALPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BALPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.40%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹13.96 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BALPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BALPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.40%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹13.96 every year
BALPHARMA Upcoming Dividends
BALPHARMA Upcoming Dividends
Cash Dividend
Ex DateEx DateSep 17, 2026
Final
Final | Div/Share: ₹1.20
Dividend/Share
₹1.20
Ex DateEx Date
Sep 17, 2026
BALPHARMA Past Dividends
BALPHARMA Past Dividends
Cash Dividend
Ex DateEx DateSep 18, 2025
Final
Final | Div/Share: ₹1.20
Dividend/Share
₹1.20
Ex DateEx Date
Sep 18, 2025
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹1.20
Dividend/Share
₹1.20
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 13, 2022
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 13, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 16, 2021
BALPHARMA Stock News & Opinions
BALPHARMA Stock News & Opinions
Articles & Videos
Corporate
Corporate
Bal Pharma Ltd. allotted warrants to promoter Shailesh Siroya for Rs 84,00,000Bal Pharma Ltd. announced the allotment of 10,00,000 warrants on a preferential basis to promoter Mr. Shailesh Siroya, for Rs 8,40,00,000, at an issue price of Rs 84 per warrant. The company received Rs 2,10,00,000, representing 25% of the total amount payable for the warrants, and the allotment was approved by the board on September 7, 2026. Each warrant is convertible into one equity share with a face value of Rs 10 and a premium of Rs 74, and can be exercised within 18 months from the allotment date.
1 week agoCapital Market - Live
Corporate
Corporate
Bal Pharma Limited announces a Rs. 1.20 per share dividend for fiscal year 2025-26Bal Pharma Limited has declared a final dividend of Rs. 1.20 per equity share, equivalent to 12% of the face value, for fiscal year 2025-26, with a record date of September 17, 2026. The company will pay the dividend on or after September 24, 2026, and tax will be deducted at source unless shareholders submit the necessary forms and documentation through MUFG Intime India Private Limited's online facility or designated email addresses.
2 weeks agoCapital Market - Live
Corporate
Corporate
Bal Pharma Limited’s board will convene August 12 to review quarterly financial resultsBal Pharma Limited will hold a board meeting on Wednesday, August 12, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Bal Pharma recommends final dividendBal Pharma announced that the Board of Directors of the Company at its meeting held on 27 May 2026, inter alia, have recommended the final dividend of Rs 1.2 per equity Share (i.e. 12%) , subject to the approval of the shareholders.
3 months agoCapital Market - Live
Earnings
Earnings
Bal Pharma consolidated net profit declines 33.89% in the March 2026 quarterNet profit of Bal Pharma declined 33.89% to Rs 3.59 crore in the quarter ended March 2026 as against Rs 5.43 crore during the previous quarter ended March 2025. Sales rose 2.69% to Rs 84.08 crore in the quarter ended March 2026 as against Rs 81.88 crore during the previous quarter ended March 2025. For the full year,net profit declined 13.02% to Rs 6.28 crore in the year ended March 2026 as against Rs 7.22 crore during the previous year ended March 2025. Sales rose 2.83% to Rs 311.66 crore in the year ended March 2026 as against Rs 303.08 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales84.0881.88 3 311.66303.08 3 OPM %12.579.33 -10.249.75 - PBDT6.284.77 32 17.0114.91 14 PBT3.222.59 24 5.935.14 15 NP3.595.43 -34 6.287.22 -13 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Bal Pharma to declare Quarterly ResultsBal Pharma will hold a meeting of the Board of Directors of the Company on 27 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Bal Pharma consolidated net profit rises 270.83% in the December 2025 quarterNet profit of Bal Pharma rose 270.83% to Rs 1.78 crore in the quarter ended December 2025 as against Rs 0.48 crore during the previous quarter ended December 2024. Sales rose 19.88% to Rs 87.69 crore in the quarter ended December 2025 as against Rs 73.15 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales87.6973.15 20 OPM %10.8810.59 - PBDT5.023.25 54 PBT1.790.57 214 NP1.780.48 271 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Bal Pharma announces board meeting dateBal Pharma will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Bal Pharma consolidated net profit declines 31.73% in the September 2025 quarterNet profit of Bal Pharma declined 31.73% to Rs 0.71 crore in the quarter ended September 2025 as against Rs 1.04 crore during the previous quarter ended September 2024. Sales rose 0.45% to Rs 74.02 crore in the quarter ended September 2025 as against Rs 73.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales74.0273.69 0 OPM %7.7410.44 - PBDT2.993.84 -22 PBT0.721.36 -47 NP0.711.04 -32 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Bal Pharma to discuss resultsBal Pharma will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.5%, vs industry avg of 11.79%
Over the last 5 years, market share decreased from 0.09% to 0.06%
Over the last 5 years, net income has grown at a yearly rate of 5.79%, vs industry avg of 10.53%